España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Ionis Pharmaceuticals
IONS
NASDAQ
Watchlist
Get Report
Perks
Buy
Compare Brokers
$45.60
0.46
1.02%
At Close: -
$45.60
0
0.00%
After Hours: 1:17 PM EDT
15 minutes delayed
Get Report
Watch
Ionis Pharmaceuticals (IONS) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Ionis Pharmaceuticals (NASDAQ:IONS) Stock
Ionis Pharmaceuticals Stock (NASDAQ: IONS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, June 27, 2024
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
Benzinga Insights
Stifel Maintains Hold on Ionis Pharmaceutical...
Benzinga Newsdesk
Tuesday, June 25, 2024
Ionis Pharmaceutics shares are trading higher...
Benzinga Newsdesk
FDA Has Accepted For Priority Review Ionis Ph...
Benzinga Newsdesk
Monday, June 24, 2024
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Avi Kapoor
Tuesday, June 18, 2024
Otsuka Pharmaceutical Obtains Exclusive Right...
Benzinga Newsdesk
Friday, June 14, 2024
Bernstein Upgrades Ionis Pharmaceuticals to M...
Benzinga Newsdesk
Monday, June 03, 2024
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Benzinga Insights
Needham Reiterates Buy on Ionis Pharmaceutica...
Benzinga Newsdesk
Friday, May 31, 2024
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
Vandana Singh
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
Vandana Singh
Ionis Discloses Positive Results From OASIS-H...
Benzinga Newsdesk
Thursday, May 23, 2024
Ionis Pharmaceuticals Will Present New Subgro...
Benzinga Newsdesk
Friday, May 17, 2024
Ionis, Biogen Down on Ending Development of ALS Drug
Zacks
Thursday, May 16, 2024
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Vandana Singh
Shares of Biogen and Ionis Pharmaceuticals ar...
Benzinga Newsdesk
Ionis And Biogen Say Development Of BIIB105 W...
Benzinga Newsdesk
Ionis Pharmaceuticals Announced Topline Data ...
Benzinga Newsdesk
Wednesday, May 08, 2024
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
Benzinga Insights
Wells Fargo Maintains Overweight on Ionis Pha...
Benzinga Newsdesk
Needham Reiterates Buy on Ionis Pharmaceutica...
Benzinga Newsdesk
Tuesday, May 07, 2024
Ionis Pharmaceuticals Reports Q1 Adjusted Net...
Benzinga Newsdesk
Ionis Pharmaceuticals Q1 2024 GAAP EPS $(0.98...
Benzinga Newsdesk
Wednesday, April 10, 2024
Wolfe Research Upgrades Ionis Pharmaceuticals...
Benzinga Newsdesk
Tuesday, April 09, 2024
The Latest Analyst Ratings For Ionis Pharmaceuticals
Benzinga Insights
Oppenheimer Maintains Outperform on Ionis Pha...
Benzinga Newsdesk
Needham Reiterates Buy on Ionis Pharmaceutica...
Benzinga Newsdesk
Sunday, April 07, 2024
Ionis Pharmaceuticals Announced Olezarsen 80 Mg Monthly Dose Met The Primary Endpoint Of Significantly Reducing Triglycerides In Patients With Genetically Validated Fcs At Six Months
Charles Gross
Monday, March 25, 2024
Ionis Pharmaceuticals To Present Olezarsen Ph...
Benzinga Newsdesk
Wednesday, March 13, 2024
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
Vandana Singh
Ionis Pharmaceuticals shares are trading high...
Benzinga Newsdesk
Ionis Announces Results from Phase 2 Study of...
Benzinga Newsdesk
Wednesday, March 06, 2024
Oppenheimer Maintains Outperform on Ionis Pha...
Benzinga Newsdesk
Biogen Announced Interim 6-month Biomarker Da...
Benzinga Newsdesk
Monday, February 26, 2024
Oppenheimer Reinstates Outperform on Ionis Ph...
Benzinga Newsdesk
Thursday, February 22, 2024
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
Benzinga Insights
Needham Reiterates Buy on Ionis Pharmaceutica...
Benzinga Newsdesk
Wednesday, February 21, 2024
Ionis Pharmaceuticals Forecasts Full Year 202...
Benzinga Newsdesk
Ionis Pharmaceuticals Q4 Adjusted EPS $0.12 M...
Benzinga Newsdesk
Earnings Scheduled For February 21, 2024
Benzinga Insights
Thursday, February 15, 2024
FDA Has Granted Orphan Drug Designation To Io...
Benzinga Newsdesk
Thursday, February 08, 2024
The FDA Has Granted Fast Track Designation To...
Benzinga Newsdesk
Thursday, February 01, 2024
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
Benzinga Insights
JP Morgan Maintains Neutral on Ionis Pharmace...
Benzinga Newsdesk
Wednesday, January 31, 2024
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Vandana Singh
Tuesday, January 30, 2024
Vect-Horus Enters License Agreement With Ioni...
Benzinga Newsdesk
Friday, January 26, 2024
RBC Capital Maintains Outperform on Ionis Pha...
Benzinga Newsdesk
Monday, January 22, 2024
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
Vandana Singh
Ionis Pharmaceuticals Announced Topline Resul...
Benzinga Newsdesk
Thursday, January 18, 2024
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch